ClinicalTrials.gg
TerminatedNCT05799183Updated Dec 31, 2024

A SHR-1210 BE Study on Healthy Subjects

A Phase 1 interventional study of SHR-1210 and SHR-1210 in Advanced Tumors, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Terminated at 1 site in China. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-31.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Basic science

Why this study was terminated
Sponsor's R\&D Strategy adjusted

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

The purpose of this study is to assess the bioequivalence of SHR-1210 before and after process changes.

02

Conditions studied

  • Advanced Tumors
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male subjects aged ≥ 18;
  2. Weigh at least 50 kg, and have a (BMI) ≥ 19 and ≤28 kg/m2;
  3. Subjects agree to use reliable measures (e.g., abstinence, sterilization, contraceptives, injectable contraceptives methylprogesterone or subcutaneous implantation in the duration of the study and for 4 months after the study drug infusion);
  4. Sign the before the trial, and fully understand the content, process and possible adverse reactions of the trial. Must be able to communicate with the investigator, understand and comply with all study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Those with a history of chronic liver, kidney, cardiovascular, neurological/psychiatric, digestive tract, respiratory, urinary, endocrine and other systemic diseases;
  2. Those with a history of diseases;
  3. Regular drinkers in the 6 months prior to the trial had an average daily alcohol intake of more than 15 g (equivalent to 145 mL of wine, 450 mL of beer, or 43 mL of liquor with 40% alcohol content);
  4. Those who are suspected or confirmed to be allergic or have had serious drug or food allergic reactions in the past, have a clear history of allergies and/or are allergic to the research drug or its ingredients;
  5. Have used any drug (including Chinese medicine and vitamins) within 2 weeks before screening, or the last dose is less than 5 half-lives of the drug from the test administration date, whichever is longer;
  6. Have used of /PD-L1 drugs;
  7. Those who have participated in other interventional clinical trials within 3 months before screening;
  8. ≥400 ml of blood loss, blood donation or receiving any blood product transfusion within 3 months before screening;
  9. Those who have undergone major surgery or hospitalized for illness within 3 months before screening;
  10. Those who have received within 6 months prior to screening, or who are expected to receive live vaccines during the study period;
  11. Those with a history of drug abuse or positive drug screening results within 12 months prior to screening;
  12. Those who have abnormalities in vital signs, physical examination, and laboratory tests during the screening period and are judged to be by the study physician (Note: If there is an abnormality and the study doctor judges that it has clinical significance, if it is within the normal range after re-examination, it can also be enrolled);
  13. There are abnormalities in the during the screening period (such as ≥ 450ms, shortened or prolonged PR interval, second-degree and third-degree atrioventricular block, pre-excitation syndrome, etc.) and are judged by the study doctor to have clinical significance;
  14. Chest x-ray (positive and lateral position) or lung CT during the screening period is abnormal and judged by the study doctor to be clinically significant;
  15. History of needle sickness and blood sickness; or those with poor vascular conditions, unable to retain implanted needles or unable to tolerate venipuncture blood collection;
  16. Those that the investigator believes are not suitable to participate in this clinical trial for other reasons.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Pre-test: ARM A

    SHR-1210 before process changes 20 mg

    Drug: SHR-1210

  • Experimental
    Pre-test: ARM B

    SHR-1210 after process changes 20 mg

    Drug: SHR-1210

  • Experimental
    Formal Test: ARM A

    SHR-1210 before process changes 20 mg

    Drug: SHR-1210

  • Experimental
    Formal Test: ARM B

    SHR-1210 after process changes 20 mg

    Drug: SHR-1210

Interventions

  • Subjects will receive treatment SHR-1210 before process changes 20 mg

  • Subjects will receive treatment SHR-1210 after process changes 20 mg

06

What researchers measure

Primary outcomes

  1. Pre-test: Incidence and severity of AE/SAE/AESI (rated based on CTCAE v5.0)

    Time frame: Day-1 to Day 46

  2. Formal Test: Pharmacokinetics parameters of SHR-1210 before and after process changes in the fed state: AUC0-inf

    Time frame: Based on pre-dose, 0.25-192 hours post-dose sampling times on Day 1 ~ Day 4 and Day 6 ~ Day 9

  3. Formal Test: Pharmacokinetics parameters of SHR-1210 before and after process changes in the fed state: the geometric mean ration

    Time frame: Based on pre-dose, 0.25-192 hours post-dose sampling times on Day 1 ~ Day 4 and Day 6 ~ Day 9

  4. Formal Test: Pharmacokinetics parameters of SHR-1210 before and after process changes in the fed state: 90% confidence interval (90% CI) of AUC0-inf

    Time frame: Based on pre-dose, 0.25-192 hours post-dose sampling times on Day 1 ~ Day 4 and Day 6 ~ Day 9

Secondary outcomes

  1. Pre-test: Inter-individual coefficient of variation (CV) of the AUC0-inf of SHR-1210

    Time frame: Based on pre-dose, 0.25-192 hours post-dose sampling times on Day 1 ~ Day 4 and Day 6 ~ Day 9

  2. Formal Test: Other Pharmacokinetics parameters of SHR-1210 before and after process changes in the fed state: Cmax

    Time frame: Based on pre-dose, 0.25-192 hours post-dose sampling times on Day 1 ~ Day 4 and Day 6 ~ Day 9

  3. Formal Test: Other Pharmacokinetics parameters of SHR-1210 before and after process changes in the fed state: AUC0-t

    Time frame: Based on pre-dose, 0.25-192 hours post-dose sampling times on Day 1 ~ Day 4 and Day 6 ~ Day 9

  4. Formal Test: Other Pharmacokinetics parameters of SHR-1210 before and after process changes in the fed state: Tmax

    Time frame: Based on pre-dose, 0.25-192 hours post-dose sampling times on Day 1 ~ Day 4 and Day 6 ~ Day 9

  5. Formal Test: Other Pharmacokinetics parameters of SHR-1210 before and after process changes in the fed state: t1/2

    Time frame: Based on pre-dose, 0.25-192 hours post-dose sampling times on Day 1 ~ Day 4 and Day 6 ~ Day 9

  6. Formal Test: Other Pharmacokinetics parameters of SHR-1210 before and after process changes in the fed state: CL

    Time frame: Based on pre-dose, 0.25-192 hours post-dose sampling times on Day 1 ~ Day 4 and Day 6 ~ Day 9

  7. Formal Test: Other Pharmacokinetics parameters of SHR-1210 before and after process changes in the fed state: Vss

    Time frame: Based on pre-dose, 0.25-192 hours post-dose sampling times on Day 1 ~ Day 4 and Day 6 ~ Day 9

  8. Formal Test: The incidence of anti-drug antibody (ADA) and neutralizing antibody (Nab) for SHR-1210

    Time frame: Based on sampling times pre-dose on Day1, post-dose on Day 9 and Day 16

  9. Formal Test: Incidence and severity of adverse events (rated based on CTCAE 5.0)

    Time frame: Day-1, Day 1 to Day 46±7

07

Study locations

1 site
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410023, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Oct 2023, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2023
First posted
Apr 5, 2023
StartActual
Jul 4, 2023
Primary completionActual
Oct 12, 2023
CompletionActual
Oct 12, 2023
Last update
Dec 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05799183
Responsible party
Sponsor
First posted
Apr 5, 2023
Start date
Jul 4, 2023
Primary completion
Oct 12, 2023
Completion
Oct 12, 2023
Last update
Dec 31, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camrelizumab

Start the discussion